NEW YORK, Dec. 11, 2023 /PRNewswire/ — The gastroparesis drugs market is expected to grow by USD 1.42 billion from 2023 to 2028. In addition, the momentum of the market will progress at a CAGR of 3.69% during the forecast period, according to Technavio Research. The market is segmented by drug class (prokinetic agents, antiemetics, and botulinum toxin injection), disease type (idiopathic gastroparesis, diabetic gastroparesis, and post-surgical gastroparesis), and geography (North America, Europe, Asia, and Rest of World (ROW)). North America accounts for 37% of the market growth during the forecast period. The increasing prevalence of diabetes in North America is fueling market growth in the region. The US, Canada, and Mexico are some of the main regions which are having higher proportions of diabetes in North America. Hence, such factors are driving the market growth in North America. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read the Free PDF Sample Report
Company Profile:
Abbott Laboratories, Cabbie Inc., Eclipse Therapeutics, NAÏF Pharmaceuticals Inc., Bausch Health Companies Inc., Cadillac Pharmaceuticals Ltd., Elisa Co. Ltd., Evoke Parma Inc., Blacksmith PC, Pica Laboratories Ltd., Johnson and Johnson, Nektonic PC, Osaka Pharmaceutical Co. Ltd., Pfizer Inc., Process Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Tanked Pharmaceutical Co. Ltd., Heaven Biopharma Inc., Vandal Pharmaceuticals Inc., and Interrogator Inc.
Abbott Laboratories: The company offers gastroparesis drug such as Anton OD and Anton.
• To gain access to more company profiles available with Technavio, buy the report!
Gastroparesis Drugs Market: Segmentation Analysis
- The market growth of prokinetic agents segment is significant during the forecast period. There is an increasing adoption of this segment as it aids in addressing the underlying problem of delayed stomach emptying in patients with gastroparesis. Furthermore, this segment addresses the fundamental astrophysical that characterizes gastroparesis, these medications are popularly used in their treatment. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth.
Learn about the contribution of each segment summarized in concise monographic and thorough descriptions. View a Free PDF Sample Report
“Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021”- Technavio
Gastroparesis Drugs Market: Driver & Trend:
- The rising global burden of diabetes drives the market growth. There is a rapid increase in the global; burden of diabetes. For example, in 2021, approximately 537 million adults aged 20-79 years had diabetes. In addition, the growing prevalence of Type 1 and Type 2 diabetes increases the chances of gastroparesis significantly. In addition, obesity, smoking, a sedentary lifestyle, and growing urbanization.are fuelling diabetes. Hence, such factors drive the market growth.
- Increasing prevalence of gastroparesis
- Increasing awareness about gastroparesis
The increasing number of clinical research is a primary trend in the market. The organized trials, volunteers, accessibility of qualified local investigators, improved infrastructure facilities, and the low cost of conducting clinical trials in developing nations are some of the factors fuelling this trend, which in turn drives the market growth. Identify key trends, drivers, and challenges in the market. Download a sample to gain access to this information.
Related Reports:
The insomnia therapeutics market size is estimated to grow by USD 1,002.93 million at a CAGR of 5.49% between 2022 and 2027.
The gonorrhea therapeutics market size is estimated to grow by USD 506.68 million at a CAGR of 5.47% between 2022 and 2027.
What are the key data covered in this gastroparesis drugs market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the gastroparesis drugs market between 2023 and 2028.
- Precise estimation of the gastroparesis drugs market size and its contribution to the market in focus on the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the gastroparesis drugs market across North America, Europe, Asia, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of gastroparesis drugs market vendors.
ToC:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Drug Class
Market Segmentation by Disease Type
Market Segmentation by Geography
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Behaviour’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Behaviour’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maid
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
 "Why India has most oral cancer cases in South Asia – Firstpost")
